BeiGene Management
Management criteria checks 2/4
BeiGene's CEO is John Oyler, appointed in Jan 2010, has a tenure of 14.25 years. total yearly compensation is $18.05M, comprised of 4.4% salary and 95.6% bonuses, including company stock and options. directly owns 3.45% of the company’s shares, worth $553.11M. The average tenure of the management team and the board of directors is 2.5 years and 4.3 years respectively.
Key information
John Oyler
Chief executive officer
US$18.0m
Total compensation
| CEO salary percentage | 4.4% |
| CEO tenure | 14.3yrs |
| CEO ownership | 3.4% |
| Management average tenure | 2.5yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21
BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?
Dec 07BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential
Oct 13EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa
Sep 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$882m |
| Sep 30 2023 | n/a | n/a | -US$959m |
| Jun 30 2023 | n/a | n/a | -US$2b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$18m | US$800k | -US$2b |
| Sep 30 2022 | n/a | n/a | -US$2b |
| Jun 30 2022 | n/a | n/a | -US$2b |
| Mar 31 2022 | n/a | n/a | -US$2b |
| Dec 31 2021 | US$17m | US$740k | -US$1b |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$1b |
| Mar 31 2021 | n/a | n/a | -US$1b |
| Dec 31 2020 | US$14m | US$696k | -US$2b |
| Sep 30 2020 | n/a | n/a | -US$2b |
| Jun 30 2020 | n/a | n/a | -US$1b |
| Mar 31 2020 | n/a | n/a | -US$1b |
| Dec 31 2019 | US$13m | US$675k | -US$949m |
| Sep 30 2019 | n/a | n/a | -US$829m |
| Jun 30 2019 | n/a | n/a | -US$665m |
| Mar 31 2019 | n/a | n/a | -US$737m |
| Dec 31 2018 | US$28m | US$650k | -US$674m |
| Sep 30 2018 | n/a | n/a | -US$505m |
| Jun 30 2018 | n/a | n/a | -US$243m |
| Mar 31 2018 | n/a | n/a | -US$147m |
| Dec 31 2017 | US$10m | US$515k | -US$93m |
Compensation vs Market: John's total compensation ($USD18.05M) is above average for companies of similar size in the US market ($USD13.52M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Oyler (55 yo)
14.3yrs
Tenure
US$18,047,667
Compensation
Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | US$18.05m | 3.45% $ 553.1m | |
| President & COO | 5.9yrs | US$10.69m | 0.060% $ 9.6m | |
| Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 14.3yrs | US$4.25m | 0.77% $ 123.7m | |
| CFO & Principal Financial Officer | 2.8yrs | US$6.96m | 0.0055% $ 885.8k | |
| Global Head of R&D | no data | US$7.00m | 0.10% $ 16.3m | |
| VP & Chief Accounting Officer | less than a year | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel & Senior VP | 1.8yrs | no data | 0.0014% $ 221.5k | |
| Chief Compliance Officer | less than a year | no data | no data | |
| Senior VP & Head of Public Affairs - Greater China | 3.3yrs | no data | no data | |
| Senior Vice President of Strategy & Corporate Development | 1.2yrs | no data | no data | |
| Senior VP & Chief Medical Officer for Solid Tumors | 2.2yrs | no data | no data |
2.5yrs
Average Tenure
53.5yo
Average Age
Experienced Management: BGNE's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.5yrs | US$18.05m | 3.45% $ 553.1m | |
| Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 8.2yrs | US$4.25m | 0.77% $ 123.7m | |
| Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board | 3yrs | no data | no data | |
| Independent Non-Executive Director & Member of the Scientific Advisory Committee | 9yrs | US$476.36k | 0.0025% $ 399.6k | |
| Independent Non-Executive Director | 11.2yrs | US$474.24k | 0.20% $ 31.5m | |
| Independent Non-Executive Director & Member of Scientific Advisory Committee | 3.7yrs | US$495.71k | 0.0013% $ 200.6k | |
| Independent Non-Executive Director | 4.3yrs | US$497.49k | 0.00057% $ 91.5k | |
| Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director | 2.2yrs | US$620.05k | 0.0012% $ 197.4k | |
| Independent Non-Executive Director | less than a year | no data | 0% $ 0 | |
| Independent Lead Director | 9.5yrs | US$478.86k | 0.0025% $ 399.6k | |
| Member of Scientific Advisory Board & Independent Non-Executive Director | 2.2yrs | US$625.78k | 0.0012% $ 197.4k |
4.3yrs
Average Tenure
64yo
Average Age
Experienced Board: BGNE's board of directors are considered experienced (4.3 years average tenure).